Andere talen TaiMed Biologics Inc.

Aandelen

4147

TW0004147004

slotkoers Taipei Exchange Andere beurzen 00:00:00 24-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
84,8 ^TWD	+2,42%		-3,53%	+3,41%

20/03	TaiMed Biologics Inc. Rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023	CI
13/03	Taimed Biologics en AcedrA Biopharmaceticals gaan samenwerken om Trogarzo te commercialiseren in het Midden-Oosten en Noord-Afrika	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

TaiMed Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03
Taimed Biologics and AcedrA Biopharmaceticals Partner to Commercialize Trogarzo in the Middle East and North Africa Region	13/03
Taimed Announces Its Marketing Partner Received Refusal to File Letter for Trogarzo Intramuscular Method of Administration sBLA from the US FDA	28/02
TaiMed Biologics Inc. Receives Patent Approval from the Taiwan Intellectual Property Office for Improving the Pharmacokinetic Performance of TMB-365 Using Histidine Modification Technology	21/02
TaiMed Biologics Inc. Announces US FDA Grants Fast Track Designation to TMB-365/TMB-380 Long-Acting Combination Therapy for HIV Infection	07/02
TaiMed Biologics Inc. Revises the Phase 2 Clinical Study Design of Bi-Monthly Dosing of TMB-365/TMB-380 Combination for the Treatment of HIV Infection	21/12
Taimed Biologics Inc. Announces US FAD Approves the sBLA for the IV Push Administration of the Loading Dose of Trogarzo	13/12
TaiMed Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Theratechnologies Reports Results from Trogarzo Intramuscular Administration Study; Tesamorelin Poster Presentation	13-10-23
TaiMed Biologics Inc. Announces Results from Trogarzo Intramuscular (IM) Administration Study	13-10-23
TaiMed Biologics Inc. Completes Data Analysis of the Clinical Trial Sentinel Group for the TMB-365 and TMB-380 Combination as Expected and Confirms the Dosing for Future Execution	06-09-23
TaiMed Biologics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11-08-23
TaiMed Biologics Inc. Completes the Last Patient Visit of the Sentinel Group in the Clinical Study Evaluating Long-Acting TMB-365/TMB-380 Combination Maintenance Therapy	28-06-23
TaiMed Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12-05-23
TaiMed Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	10-03-23
TaiMed Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	10-03-23
TaiMed Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	11-11-22
US FDA Approves the Supplemental Biologicslicense Application for Intravenous (IV) Pushadministration of Trogarzo	03-10-22
TaiMed Biologics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	15-08-22
TaiMed Biologics : First Patient Enrolled in the Study Evaluating Bi-monthly and Quarterly Dosing of the Long-Acting TMB-365/TMB-380 mAb Combination Maintenance Therapy	29-07-22

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen TaiMed Biologics Inc.

Aandelen

4147

TW0004147004

Andere talen

Filters